MBX Biosciences, Inc. (MBX): R&D Expense
$79.16M
Year ended 2025-12-31
$88.49M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $79.16M | +37.9% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $57.41M | +101.2% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $28.53M | n/a | 2025-03-17, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| MBX Biosciences, Inc. (MBX) | 2025-12-31 | $79.16M | +37.9% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $168.06M | +20.8% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $31.16M | +21.9% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $142.27M | +13.5% |
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $4.4K | n/a |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $62.36M | +65.6% |
| Erasca, Inc. (ERAS) | 2025-12-31 | $92.85M | -19.5% |
| Ironwood Pharmaceuticals Inc (IRWD) | 2025-12-31 | $95.14M | -14.6% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $132.16M | -8.2% |
Compare MBX, ZBIO, XERS, TRDA side by side · Screen every company in Pharmaceutical Preparations ↗